We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microgen | LSE:MCGN | London | Ordinary Share | GB00BVVHWX30 | ORD 6 3/7P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 367.50 | 365.00 | 370.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2017 08:28 | Seems to be a very good use of there cash by increasing their recurring revenues. A great fit with Aptitude and there growing presence in North America.Earnings enhancing in 2018. | shauney2 | |
31/8/2017 08:22 | Acquisition of RevStream Microgen plc ('Microgen') is pleased to announce the acquisition of RevStream Inc. ('RevStream'), a California-based provider of revenue management enterprise software. The acquisition broadens and complements the specialist capabilities within Microgen's Aptitude Software business ('Aptitude') and provides access to RevStream's growing client base in the technology sector. RevStream will be integrated into Aptitude which already has an established office in Boston and a strong North American presence with over 50% of H1 2017 Aptitude revenues generated in the US and Canada. Since 2015 Aptitude has established a market leading position in the telecommunications sector with the Aptitude Revenue Recognition Engine ('ARRE'), an application which enables organisations to address the requirements of IFRS 15 and ASC 606. ARRE has established this strong position as a result of its capability to process very rapidly a very high volume of complex, business event-driven transactions and calculations. The acquisition of RevStream enables Aptitude to offer broader revenue management functionality which augments the specialised capabilities of ARRE. RevStream's growing client base, primarily focussed on the technology sector, complements Aptitude's strong presence within the financial services, insurance and telecommunications sectors and provides cross-selling opportunities for both organisations' products. In addition, RevStream's existing cloud capabilities will be leveraged across Aptitude's new applications where cloud deployment is appropriate. | shauney2 | |
14/8/2017 12:16 | Looking very firm here.Noticed some large sells last week and the price hardly budged. | shauney2 | |
04/8/2017 10:28 | Holdings RNS. Old Mutual increased again recently, now above 11.5%. | djbilywiz | |
24/7/2017 09:47 | Solid results as expected. | djbilywiz | |
21/7/2017 07:39 | Didn't invest here but it was a share I had on my watch list. Well done all long term holders. Reap your rewards. | leadersoffice | |
20/7/2017 02:58 | Last two trades 19 July have a 20p spread. Very strong price considering the large sell trade mid afternoon. Looking forward to the numbers next week. | coincall | |
11/7/2017 12:06 | Looking very firm.Buyers at 402p now and 401p to sell.Needs to hold at the end of the day of course. Some big trades around with one of 2 million yesterday. | shauney2 | |
11/7/2017 11:34 | Microgem is off again will it crack 4 quid today ? | 2bluelynn | |
07/7/2017 10:12 | From the Daily Mail market report IT firm Microgen shot up to an all-time high after reporting ‘exceptional growth’ in its technology designed to make finance bosses’ lives easier. It said revenue from its software used to help with number crunching, forecasting results, and accounting grew 42 per cent to £15m since June last year. As a result, Microgen said financial performance for the whole of 2017 is like to be significantly ahead of expectations. Brokers at Investec reinstated their ‘buy’ rating for the stock and upgraded their price target from 330p to 400p. Shares rose 18.2 per cent, or 57.5p, to 374p. Read more: I think the all time high was over 10 quid during the dot com bubble around 2000 | shauney2 | |
06/7/2017 12:27 | Suspect this will break through 400p on or before results. As shauney2 says above, this unscheduled RNS means that results will be at least 10% ahead. Enjoying the ride! | martinthebrave | |
06/7/2017 12:24 | A very strong trading update this morning, couldn't resist buying into MCGN at the open. It would seem that the performance of Aptitude Software has surpassed management expectations which has led to today's significantly ahead statements, it is reassuring that they are confident that this strong performance will continue into H2. Nice to come across a company with a strong balance sheet, high margins and an accelerating business performance, chart is strong also with a new breakout this morning. | interceptor2 | |
06/7/2017 12:04 | They can't contain themselves indeed brucey. That was an unscheduled trading update so i guess they were duty bound to inform the market if they are significantly ahead. Significantly should see all the metrics up more than 10% at least including the net cash which was £13.6m at the last count. I like the growth in the Financial Systems revenue which should offset the moderation in ARRE into 2018. | shauney2 | |
06/7/2017 09:10 | Interims in 3 weeks. They can hardly contain themselves. | bruceylegs | |
06/7/2017 07:41 | Another positive statement as the growth continues. ''significantly ahead of the Board's expectations for the year.'' | djbilywiz | |
25/5/2017 14:24 | I sold a few.Was reluctant but the chart seemed to be rolling over.Will buy back lower if they do drop further before results in July. | shauney2 | |
25/5/2017 13:09 | I'm out. Good run but i think it will drop to 300p when I'll reconsider. | petewy | |
15/5/2017 08:24 | From Citywire Citywire AAA-rated small-cap veteran Dan Nickols has ramped up a recent run of purchases in wealth management and accounting software specialist Microgen (MCGN.L) as its shares continue to climb. Nickols increased his holding in the business from 3.8 million to just over five million shares, a stake worth £16.8 million at a share price of 334p, which has risen threefold since early last year. Most of the shares are held in his £1.1 billion Old Mutual UK Smaller Companies fund with the remainder held in his colleague Nick Williamson’s £188 million Smaller Companies Focus funds. In 2016 results Microgen chair Ivan Martin hailed ‘record numbers’ of new contracts signed in the year, driving revenue 35% higher to £43 million, and its operating margin 30% higher at 15%. While consistently rating the business a buy, analysts at Investec have struggled to keep pace with the rally, which has already outstripped a late April price target of 330p. | shauney2 | |
08/5/2017 11:15 | All the big trades going on ! is there something in the mix I wonder | 2bluelynn | |
05/5/2017 14:21 | Seems not shauney2! | coincall | |
04/5/2017 13:39 | Ex dividend today and barely a blip. Surely it will drift down until the results in July. | shauney2 | |
27/4/2017 07:21 | Didn't realise that Ivan Martin is also at FDM, another of my holdings. A good sign as they're going great guns as well. He obviously knows what he's doing. | firtashia | |
24/4/2017 19:40 | This has been such a good share for me ,keeps on performing . I thought there might be a big rise today then a big pull back at close with a horrible shooting stat doji candle . Never happened lovely .. ... good Dividends and good management Thumbs up from me | 2bluelynn | |
24/4/2017 15:52 | Abnormally high volume traded today; whilst its a perfectly good update I didnt think it would drive such a positive response in the share price. Not complaining though. | firtashia | |
24/4/2017 13:43 | Yes very nice update today, and could see further buying IMO. Aptitude Software seems to be the jewel in the crown, with contract wins proving the growth story in the US healthcare market. | djbilywiz |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions